Browsing Over 990 Presentations

Sort By

Panel discussion on management of mBC in Asian patients (ID 1793)

South Korea’s journey with precision oncology (ID 1798)

Is immuno-oncology going to replace chemotherapy in advanced HNSCC? (ID 1803)

ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC ESMO Colloquium

Future development for the use of biomarkers

Lecture Time
01:40 PM - 02:05 PM
Session Name
ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC
Speakers
  • Ross A. Soo
Location
Hall 407, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
12:45 PM - 02:15 PM
Authors
  • Ross A. Soo

Charting the course for the stage III NSCLC patient (ID 1780)

What’s new in metastatic pancreatic cancer management? (ID 1785)

Introduction of Speaker (ID 1791)

The clinical significance of comprehensive genomic profiling (ID 1796)

Expert Opinion on ‘PARP inhibitors as targeted therapy for personalized medicine’ - Panel Discussion (ID 1882)

Welcome, introductions and objectives of the session (ID 1801)

ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC ESMO Colloquium

Immune-Check Points Inhibitors (ICI) in non-oncogenic addicted mNSCLC

Lecture Time
12:50 PM - 01:15 PM
Session Name
ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC
Speakers
  • Marina C. Garassino
Location
Hall 407, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
12:45 PM - 02:15 PM
Authors
  • Marina C. Garassino

Introduction (ID 1783)